Valeant Pharmaceuticals Inc.'s missed Phase IIa endpoint last week with retigabine for pain in postherpetic neuralgia leaves intact the promise proven in Phase III for epilepsy - albeit a promise somewhat limited by the dosing schedule of the potassium channel opener, subject of a lucrative year-ago deal with GlaxoSmithKline plc. Read More
